Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sagar S Mukhida

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Current Treatment Options in Oncology|April 29, 2025
Advances in Targeted Therapy for Metastatic Prostate CancerKabir Grewal, Tanya B Dorff, Sagar S Mukhida, et al.
The Oncologist|April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCCAndrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
European Urology Focus|September 22, 2024
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell CarcinomaEmily Wang, Eric S Rupe, Sagar S Mukhida, et al.
Urologic Oncology|July 5, 2025
Vigorous physical activity as a potential environmental risk factor in renal medullary carcinomaDaniel D Shapiro, Sagar S Mukhida, Andrew W Hahn, et al.
The American Journal of Cardiology|February 18, 2026
Femoropopliteal Artery Atherectomy for Symptomatic Peripheral Artery Disease in the XLPAD RegistryMinseob Jeong, Anand Gupta, Sameh Sayfo, et al.
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinomaKabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Current Treatment Options in Oncology|April 29, 2025
Advances in Targeted Therapy for Metastatic Prostate CancerKabir Grewal, Tanya B Dorff, Sagar S Mukhida, et al.
The Oncologist|April 11, 2025
A phase II trial of sitravatinib + nivolumab after progression on immune checkpoint inhibitor in patients with metastatic clear cell RCCAndrew W Hahn, Nabil Adra, Ulka Vaishampayan, et al.
European Urology Focus|September 22, 2024
Belzutifan Efficacy and Tolerability in Patients with Sporadic Metastatic Clear Cell Renal Cell CarcinomaEmily Wang, Eric S Rupe, Sagar S Mukhida, et al.
Urologic Oncology|July 5, 2025
Vigorous physical activity as a potential environmental risk factor in renal medullary carcinomaDaniel D Shapiro, Sagar S Mukhida, Andrew W Hahn, et al.
The American Journal of Cardiology|February 18, 2026
Femoropopliteal Artery Atherectomy for Symptomatic Peripheral Artery Disease in the XLPAD RegistryMinseob Jeong, Anand Gupta, Sameh Sayfo, et al.
Endocrine-Related Cancer|September 26, 2024
Body composition in recurrent prostate cancer and the role of steroidogenic genotypeNeha Venkatesh, Rebecca S Tidwell, Yao Yu, et al.
JCO Oncology Practice|November 7, 2025
Evaluating Clinical Tools to Monitor Cardiovascular Risk in Men With Prostate Cancer Receiving Hormone TherapyNeha Venkatesh, Pankaj Kumar Chauhan, Sagar S Mukhida, et al.
Journal for Immunotherapy of Cancer|March 3, 2026
Influence of body composition on the efficacy of nivolumab plus ipilimumab for metastatic clear cell renal cell carcinomaKabir Grewal, Maria Julia Moura Nascimento Santos, Pankaj Kumar Chauhan, et al.
Pageof 1